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background:  Effects of atorvastatin on lipid-rich plaques between patients with ST-segment elevation myocardial infarction (STEMI) and 
non-ST-segment elevation acute coronary syndrome (NSTEACS) remain unclear.
methods:  Thirty-six patients with ACS (STEMI=11, NSTEACS=25) were included in the study. They were treated with atorvastatin 60mg/
day or 20mg/day. Serial optical coherence tomography (OCT) and intravascular ultrasound (IVUS) were performed at baseline and 
12-month follow-up for non-culprit lipid-rich plaques. Fibrous cap thickness (FCT) and lipid arc were measured by OCT. Total atheroma 
volume (TAV), normalized total atheroma volume (NTAV) and percentage atheroma volume (PAV) were measured by IVUS.
Results:  A total of 51lipid-rich plaques (STEMI group=15, NSTEACS group=36) were analyzed. There were no significant differences 
in baseline characteristics and atorvastatin treatment between 2 groups. OCT demonstrated a significant increase in FCT in STEMI and 
NSTEACS (p<0.001, p<0.001, respectively). Maximum lipid arc was reduced significantly in NSTEACS (247.0±71.2° to 201.5±72.1°; 
p<0.001), such change was not observed in STEMI (p=0.102). In STEMI patients, PAV was increased significantly (54.0±10.3% to 
56.1±9.8%; p=0.049), whereas no change was observed in NSTEACS (p=0.167). A significant decrease of NTAV was apparent in 
NSTEACS (98.5±42.1mm3 to 93.7±40.6mm3; p=0.039) but not observed in STEMI (p=0.385). Differences in absolute changes in PAV 
(2.1±3.9% versus -1.1±4.4%; p=0.018) and percentage changes in PAV (4.5±8.0% versus -2.1±8.3%; p=0.013) between STEMI and 
NSTEACS were significant.
conclusion:  One-year atorvastatin treatment showed better effects on lipid-rich plaques in patients with NSTEACS compared with those 
with STEMI.
